Acute HIV: Low-Positive RNA With Negative Serology

Assume the RNA assay is 100% sensitive in acute HIV and 99.5% specific in this population:

• True positives: 0.004 x 1.00 = 0.00400
• False positives: 0.996 x 0.005 = 0.00498
• PPV = 0.00400 / (0.00400 + 0.00498) = about 45%

So even a positive RNA in this low-prevalence setting is roughly a coin flip on mathematics alone - which is why the result must be interpreted with the clinical picture.

Why the number is not the answer:

• The prior probability here is far above 0.4%. A three-week post-exposure febrile rash illness with lymphadenopathy, transaminitis, thrombocytopenia, and leukopenia is a classic acute retroviral syndrome; a realistic pre-test probability is well above 50%, which drives the post-test probability into the high 90s.
• False-positive RNA results are usually very low (tens of copies), often near the limit of detection. A value of 1,850 copies/mL with a normal internal control is not the typical profile of a spurious result.
• The 4th-generation antigen/antibody assay is expected to be negative at three weeks in a substantial fraction of true early infections; a negative antibody result is compatible with, not evidence against, acute HIV.

Order:

• A repeat HIV-1 RNA from a newly collected specimen, ideally with an assay that reports the full quantitative range, plus a repeat 4th-generation antigen/antibody test on the same draw (seroconversion may already be occurring).
• HIV-1/2 differentiation immunoassay again at follow-up, and if any reactivity appears, HIV-1/HIV-2 nucleic acid differentiation to identify the type.
• Baseline resistance genotype is appropriate if acute HIV is confirmed, since transmitted drug resistance is common.
• Exclude alternative diagnoses that mimic the syndrome: EBV/CMV, secondary syphilis, acute hepatitis A/B/C, and other viral exanthems.
• Baseline CD4, viral load, renal/hepatic function, HLA-B*57:01 if abacavir is contemplated.

Therapy advice: do not delay for a repeat result when the clinical suspicion and RNA value are concordant - acute HIV is the period of highest transmission risk and starting ART is low risk. Confirm in parallel and document the reasoning; a confirmatory result should be obtained before the diagnosis is entered as definitive in the record, and the patient should be counseled that confirmation is pending.

This is a discordant result that must not be resolved by choosing the answer you prefer. Two possibilities remain open:

• False-positive initial RNA (technical: low-level contamination, primer/probe cross-reactivity, specimen mix-up). This becomes more likely if both the repeat RNA and serology stay negative and the clinical syndrome has another explanation.
• Resolving acute infection with transient low-level viremia - less typical, since untreated acute HIV viremia usually rises rather than becomes undetectable within four days, and serology should begin to convert within one to three weeks.

Follow-up plan:

• Document the discrepancy and have a second technologist review specimens and accessioning for a possible mix-up.
• Repeat HIV-1/2 antigen/antibody plus RNA at two and four weeks; a negative antibody at four to six weeks past exposure is strong evidence against HIV.
• Pursue alternative diagnoses actively (EBV/CMV serology and PCR, syphilis serology, hepatitis panel).
• Counsel on risk reduction and offer pre-exposure prophylaxis if HIV is ultimately excluded.
• If acute HIV is subsequently confirmed, review why the earlier RNA was negative - for example, an inhibition or input problem - as a quality investigation.